Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 10, 2020

Enanta advances HBV candidate EDP-514 in Phase I trials

Enanta Pharmaceuticals has launched a Phase Ib clinical trial of EDP-514, a hepatitis B virus (HBV) core inhibitor, in viremic HBV patients.

Enanta Pharmaceuticals has launched a Phase Ib clinical trial of EDP-514, a hepatitis B virus (HBV) core inhibitor, in viremic HBV patients.

The company also restarted its ongoing Phase Ib trial in HBV patients who were treated with a nucleos(t)ide reverse transcriptase inhibitor (NUC-suppressed patients). This trial was temporarily paused due to the Covid-19 pandemic.

Core inhibitors are known to act by targeting various steps in the HBV lifecycle.

In preclinical studies, EDP-514 was able to inhibit HBV replication and prevent the denovo formation of new cccDNA in primary human hepatocytes when administered in the early stages of the infection.

Enanta Pharmaceuticals president and CEO Jay Luly said: “EDP-514, a novel core inhibitor of HBV replication, leverages our strength in compound optimisation and targeted rational design, enabling potent anti-HBV activity at multiple steps in the HBV lifecycle.

“We are excited to further investigate EDP-514 in viremic HBV patients, and look forward to reporting preliminary safety and virologic data in the first half of 2021, while also completing our study in NUC-suppressed patients with top-line data expected in the second quarter of 2021.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The randomised, double-blind, placebo-controlled Phase Ib study in viremic chronic HBV patients will assess the safety, tolerability, pharmacokinetics, and antiviral activity of three ascending doses of oral EDP-514 over 28 days in 24 subjects.

Meanwhile, the Phase Ib study in NUC-suppressed patients is the second part of a Phase Ia/Ib trial.

This Phase Ib part will also investigate the safety, tolerability, pharmacokinetics, and antiviral activity of three ascending doses of oral formulation of the drug candidate in 24 participants.

The first part of the Phase Ia/Ib trial tested EDP-514 in healthy subjects, who were given single or multiple doses for up to 14 days. EDP-514 was observed to be well tolerated, with a favourable safety profile.

During the study, treatment-emergent adverse events were reported to be infrequent and mild in intensity.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU